| Literature DB >> 24693939 |
Adiphol Dilokpimol, Christian Peter Poulsen, György Vereb, Satoshi Kaneko, Alexander Schulz, Naomi Geshi1.
Abstract
BACKGROUND:Entities:
Mesh:
Substances:
Year: 2014 PMID: 24693939 PMCID: PMC4234293 DOI: 10.1186/1471-2229-14-90
Source DB: PubMed Journal: BMC Plant Biol ISSN: 1471-2229 Impact factor: 4.215
Figure 1Identification of donor substrate for recombinant AtGALT29A. Affinity purified AtGALT29A (■) or P19 (□) was incubated with A: NDP-[14C]-sugars: UDP-[14C]-Xyl, UDP-[14C]-Glc, GDP-[14C]-Man and GDP-[14C]-Fuc (as MixI), and UDP-[14C]-GlcNAc, UDP-[14C]-GlcA and UDP-[14C]-Gal (as MixII); B: or individual NDP-[14C]-sugars from MixII using GAGP8 as acceptor substrate. Error bars showed standard deviations from n = 4. The result indicates that UDP-[14C]-Gal serves substrate for AtGALT29A.
Figure 2Subcellular localization of AtGALT29A-mCer3 in leaves. A-B: Confocal images of AtGALT29A-mCer3, STtmd-YFP (a Golgi marker) co-expressed transiently in N. benthamiana leaves. C: The overlay image of (A) and (B). The result indicates co-localization of ATGALT29A-mCer3 and STtmd-YFP in the Golgi apparatus. Scale bar = 5 μm.
Figure 3Localization and FRET analysis for AtGALT29A and AtGALT31A. A-B: Confocal images of AtGALT31A-mCer3 and AtGALT29A-YFP co-expressed in N. benthamiana leaves. C: The overlay image of (A) and (B). AtGALT31A-mCer3 and AtGALT29A-YFP are co-localized in high frequency. D-G: Distribution histogram for pixel by pixel analysis of FRET [26]. FRET efficiency is expressed as FRET=, for example, FRET = 0.19 in (D) means that FRET efficiency is 19%; SEM, standard error of means; cell = number of cells analyzed. Scale bar = 5 μm.
Figure 4Galactosyltransferase activity using the purified AtGALT29A/AtGALT31A complex . Microsomes were prepared from N. benthamiana leaves after expression of P19 only, AtGALT31A-GFP, HA-AtGALT29A or co-expression of HA-AtGALT29A and AtGALT31A-GFP, and subjected to immunoprecipitation using anti-GFP- or anti-HA-antibody. The conditions are indicated in the table at the bottom of (B). The immunoprecipitated samples were analyzed by the Western blot (A) and by the enzyme activity (B). A: The Western blot of P19, AtGALT31A-GFP, HA-AtGALT29A and AtGALT29A/AtGALT31A immunoprecipitated using GFP antibody. The result indicates co-purification of AtGALT31A-GFP (lane 5, indicated by the arrow at ca. 70 kDa) by immunoprecipitation of HA-AtGALT29A using anti-HA-antibody-agarose. The 50 kDa band detected in the lanes 3-5 is the heavy chain of HA antibody used for the immunoprecipitation, which is recognized by the secondary antibody used in the Western blot. B: Galactosyltransferase activity towards SP32-GFP and β-1,3-galactan acceptors. Affinity purified materials from the expression of P19 only, AtGALT31A-GFP, HA-AtGALT29A, or co-expression of HA-AtGALT29A and AtGALT31A-GFP using anti-GFP- or anti-HA-antibody were tested for enzyme activity using UDP-14[C]-Gal as substrate and SP32-GFP (lanes 1-5) or β-1,3-galactan (lanes 8-10) as acceptor, (n = 4). Control samples after co-expression of AtGALT31A-GFP or HA-AtGALT29A with HA-AtGLCAT14A (lane 6 and 7) were immunoprecipitated in the same way as for other samples and tested for the enzyme activity using UDP-14[C]-Gal as substrate and SP32-GFP as acceptor (lanes 6-7), (n = 3). These combinations are not suggested to form protein complexes based on the FRET analysis. Error bars showed standard deviations.
Figure 5Simplified model structure of arabinogalactan and reaction sites of enzymes. The cleavage sites of the hydrolases (exo-β-1,3-galactanase, endo-β-1,6-galactanase, α-arabinofuranosidase) used in this paper are indicated. Recombinant AtGALT29A produced Gal incorporated products susceptible to the treatment of endo-β-1,6- and exo-β-1,3-galactanases (Figure 6), therefore three possible sites (β1 → 6a, b and β1 → 3c) are conceivable as the candidate sites of reaction. Towards β-1,3-galactan acceptor, both β1 → 6b and β1 → 3c galactosyltransferase activities are possible, but the main compound released by the exo-β-1,3-galactanase treatment was galactobiose, and not galactose (inset TLC in Figure 6C, D), indicating a β1 → 6b activity rather than β1 → 3c activity. Together with the β1 → 6a activity indicated by the endo-β-1,6-galactanase treatment, it is concluded that, AtGALT29A possesses β-1,6-galactosyltransferase activities both on β-1,3- and β-1,6-galactan (β1 → 6a, b activities).
Figure 6Analysis of the sites of Gal incorporation in the products produced by AtGALT29A alone or the AtGALT29A/AtGALT31A complex. The [14C]-Gal incorporated products onto SP32-GFP (A, B, C) or onto β-1,3-galactan (D) from P19 [∙∙∙], HA-AtGALT29A [---], or co-immunoprecipitated HA-AtGALT29A/AtGALT31A-GFP complex [▬] were treated with A: endo-β-1,6-galactanase, B: endo-β-1,6-galactanase + α-arabinofuranosidase, C: exo-β-1,3-galactanase, or D: exo-β-1,3-galactanase, and separated by size exclusion chromatography using Superdex Peptide HR 10/30. The [14C]-Gal present in each fraction was evaluated by scintillation counting. Endo-β-1,6-galactanase, α-arabinofuranosidase, and exo-β-1,3-galactanase used in this study cleave β-1,6-linked unsubstituted galactotriose, terminal α-linked arabinofuranose, and β-1,3-linked galactooligosaccharides regardless the presence or absence of substitutions, respectively. Release of small [14C]-oligosaccharides by endo-β-1,6-galactanase indicates the [14C]-Gal incorporation to a part of β-1,6-galactotriose, while exo-β-1,3-galactanase releases [14C]-Gal monomer from β-1,3-linked galactan and [14C]-oligosaccharide (s) from side chains attached to β-1,3-linked galactan. From the [14C]-products made onto SP32-GFP and β-1,3-galactan, exo-β-1,3-galactanase released mainly [14C]-galactobiose analyzed by TLC (inset C and D), indicating the incorporation of single [14C]-Gal to β-1,3-linked Gal at O6 in the [14C]-products. From any treatments (A-D), higher amount of small [14C]-oligosaccharides are released from the [14C]-products made by AtGALT29A/AtGALT31A complex compared to that from a single enzyme. The results indicate that AtGALT29A possesses β-1,6-GalT activities elongating β-1,6-galactan and forming 6-Gal branches on β-1,3-galatan, and the β-1,6-GalT activities are increased when AtGALT29A is in a protein complex with AtGALT31A.
Figure 7Galactosyltransferase activity in intact microsomes isolated from after co-expression of -and . Microsomes were incubated with exogenously added UDP-[14C]-Gal and the [14C]-Gal incorporation to luminal endogenous materials were analyzed by precipitation either by A: 70% ethanol or B: β-Gal Yariv reagent. Error bars showed standard deviations from n = 4.